文献速递血脂与心血管预防冠心病肺血管病与心包/心肌炎

基因阳性家族性高胆固醇血症的管理与后果

Management and Consequences of Genotype-Positive Familial Hypercholesterolemia.
PubMed 文献 · JAMA Cardiol · 2026-01-01

基于美国All of Us队列245 388名成人全基因组测序数据,基因阳性家族性高胆固醇血症(FH)患病率为0.35%(95%CI 0.33%-0.38%)。FH携带者冠心病、外周动脉疾病及短暂性脑缺血发作或卒中风险显著高于非携带者,但仅少数达到指南推荐的LDL-C目标。

要点

  • 基因阳性FH在All of Us队列中患病率为0.35%(1/287),存在州级差异。
  • FH携带者冠心病风险显著增高(OR 2.91,95%CI 2.34-3.58)。
  • 仅30.1%的FH携带者最近LDL-C<100 mg/dL,显著低于非携带者的48.2%。

核心结论

  • 基因阳性FH在All of Us参与者中患病率为0.35%(95%CI 0.33%-0.38%),且存在州级差异。
  • 少数基因阳性FH个体达到指南推荐的LDL-C目标,且动脉粥样硬化性心血管疾病发生率增高。

研究设计与样本

  • All of Us队列研究,分析2018年5月至2022年7月入组的美国成年参与者全基因组测序和表型数据。
  • 共纳入245 388名参与者,平均(SD)年龄56.5(16.9)岁,女性145 563名(59.3%)。
  • 对LDLR、APOB和PCSK9基因中的FH变异(致病或可能致病)按标准标准进行人工分类。

主要发现

  • 基因阳性FH identified in 865名参与者,患病率0.35%(95%CI 0.33%-0.38%),即1/287。
  • FH携带者中349名(40%)被处方他汀,332名(38.4%)测量了LDL-C。
  • 冠心病、外周动脉疾病、短暂性脑缺血发作或卒中在FH携带者中显著更常见(冠心病OR 2.91,95%CI 2.34-3.58;外周动脉疾病OR 1.51,95%CI 1.16-1.96;短暂性脑缺血发作或卒中OR 1.54,95%CI 1.11-2.09)。
  • 仅30.1%的FH变异阳性参与者最近LDL-C<100 mg/dL,而非携带者为48.2%(P<.001)。
  • 在合并ASCVD且处方降脂治疗的总参与者中,FH个体达到二级预防LDL-C目标(<70 mg/dL)的比例显著更少(19.33% vs 43.12%,P<.001)。

关键数值与推荐

  • 基因阳性FH定义为LDLR、APOB或PCSK9基因中致病或可能致病变异。
  • 指南基于的LDL-C目标包括一般<100 mg/dL和二级预防<70 mg/dL。

临床怎么用

  • 在临床实践中应关注基因阳性FH患者,其ASCVD风险显著增高,需积极降脂管理。
  • 多数FH携带者未达到指南推荐的LDL-C目标,提示需加强他汀处方和LDL-C监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Familial hypercholesterolemia (FH) is a common genetic condition that causes hypercholesterolemia and increased risk for premature atherosclerotic cardiovascular disease (ASCVD). The prevalence, management, and consequences of genetically confirmed FH across the US are poorly understood. OBJECTIVE: To identify genotype-positive FH in a national US cohort and describe its prevalence, consequences, and lipid-lowering management. DESIGN, SETTING, AND PARTICIPANTS: In the All of Us (AoU) cohort study, whole-genome sequencing and phenotypic data from US adult participants enrolled between May 2018 and July 2022 were analyzed to identify and study genotype-positive FH. Data were analyzed between May 2024 and May 2025. EXPOSURE: FH variants (pathogenic or likely pathogenic) in LDLR, APOB, and PCSK9 genes were manually classified with standard criteria. MAIN OUTCOMES AND MEASURES: The primary outcomes were demographic characteristics, lipid measurements, ASCVD, and prevalence of FH and noncarriers in AoU. Lipid management was then characterized among individuals with FH through lipid-lowering therapy (LLT) documentation and guideline-based low-density lipoprotein cholesterol (LDL-C) targets. RESULTS: A total of 245 388 participants were included, with mean (SD) age of 56.5 (16.9) years and 145 563 female participants (59.3%). Genotype-positive FH was identified in 865 participants (prevalence, 0.35%; 95% CI, 0.33%-0.38%; 1 in 287 participants). Among individuals with genotype-positive FH, 349 (40%) were prescribed statins, and 332 (38.4%) had LDL-C measured. Coronary artery disease, peripheral artery disease, and transient ischemic attack or stroke were significantly more common in genotype-positive FH carriers compared to noncarriers (coronary artery disease: odds ratio [OR], 2.91; 95% CI, 2.34-3.58; peripheral artery disease: OR, 1.51; 95% CI, 1.16-1.96; and transient ischemic attack or stroke: OR, 1.54; 95% CI, 1.11-2.09). Only 30.1% of participants positive for FH variants had LDL-C less than 100 mg/dL at their most recent result compared to 48.2% of noncarriers (P < .001). Of the total participants with ASCVD and LLT prescription, significantly fewer individuals with FH met the secondary prevention LDL-C target (<70 mg/dL; 19.33% vs 43.12%; P < .001) compared to noncarriers. CONCLUSIONS AND RELEVANCE: This cohort study finds a prevalence of genotype-positive FH in All of Us participants of 0.35% (95% CI, 0.33%-0.38%), with state-level variation. A minority of individuals with genotype-positive FH met guideline-recommended LDL-C targets and had increased rates of ASCVD.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Spinks C, Selvaraj MS, Robinson C, et al. Management and Consequences of Genotype-Positive Familial Hypercholesterolemia. JAMA Cardiol. 2026. PMID: 41779414. doi:10.1001/jamacardio.2026.0006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。